Literature DB >> 15821891

Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine.

G Piazzolla1, M Nuzzaci, C Tortorella, E Panella, A Natilla, D Boscia, A De Stradis, P Piazzolla, S Antonaci.   

Abstract

A vaccine against Hepatitis C virus (HCV) is urgently needed due to the unsatisfactory clinical response to current therapies. We evaluated the immunological properties of a chimeric Cucumber mosaic virus (CMV), a plant virus engineered to express on its surface a synthetic peptide derived from many HVR1 sequences of the HCV envelope protein E2 (R9 mimotope). Evidence was obtained that the chimeric R9-CMV elicits a specific humoral response in rabbits. Furthermore, in patients with chronic HCV infection, purified preparations of R9-CMV down-modulated the lymphocyte surface density of CD3 and CD8, and induced a significant release of interferon (IFN)-gamma, interleukin (IL)-12 p70 and IL-15 by lymphomonocyte cultures. Finally, an R9 mimotope-specific CD8 T-cell response, as assessed by intracellular IFN-gamma production, was achieved in the majority of the patients studied. Our results open up new prospects for the development of effective vaccines against HCV infection. Moreover, the wide edible host range of CMV makes the production of an edible vaccine conceivable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15821891     DOI: 10.1007/s10875-005-2820-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  56 in total

1.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies.

Authors:  N Savelyeva; R Munday; M B Spellerberg; G P Lomonossoff; F K Stevenson
Journal:  Nat Biotechnol       Date:  2001-08       Impact factor: 54.908

3.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

Authors:  J Banchereau; A K Palucka; M Dhodapkar; S Burkeholder; N Taquet; A Rolland; S Taquet; S Coquery; K M Wittkowski; N Bhardwaj; L Pineiro; R Steinman; J Fay
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

4.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 5.  Immunopathogenesis of hepatitis C virus infection.

Authors:  A J Freeman; G Marinos; R A Ffrench; A R Lloyd
Journal:  Immunol Cell Biol       Date:  2001-12       Impact factor: 5.126

6.  CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained.

Authors:  F Lechner; N H Gruener; S Urbani; J Uggeri; T Santantonio; A R Kammer; A Cerny; R Phillips; C Ferrari; G R Pape; P Klenerman
Journal:  Eur J Immunol       Date:  2000-09       Impact factor: 5.532

Review 7.  Hepatitis C: an epidemiological review.

Authors:  M I Memon; M A Memon
Journal:  J Viral Hepat       Date:  2002-03       Impact factor: 3.728

8.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

9.  Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication.

Authors:  N Harris; R M Buller; G Karupiah
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  11 in total

1.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

Review 2.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

Review 3.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

4.  Apoptotic effects of a chimeric plant virus carrying a mimotope of the hepatitis C virus hypervariable region 1: role of caspases and endoplasmic reticulum-stress.

Authors:  G Piazzolla; M Nuzzaci; A Vitti; N Napoli; M Schiavone; P Piazzolla; S Antonaci; C Tortorella
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

5.  Immune response to a potyvirus with exposed amino groups available for chemical conjugation.

Authors:  Carlos Alberto Manuel-Cabrera; Ana Márquez-Aguirre; Hernández-Gutiérrez Rodolfo; Pablo César Ortiz-Lazareno; Gabriela Chavez-Calvillo; Mauricio Carrillo-Tripp; Laura Silva-Rosales; Abel Gutiérrez-Ortega
Journal:  Virol J       Date:  2012-03-27       Impact factor: 4.099

Review 6.  Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.

Authors:  Marie-Ève Lebel; Karine Chartrand; Denis Leclerc; Alain Lamarre
Journal:  Vaccines (Basel)       Date:  2015-08-05

Review 7.  Plant-based vaccines against viruses.

Authors:  Edward P Rybicki
Journal:  Virol J       Date:  2014-12-03       Impact factor: 4.099

8.  Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Authors:  Mona O Mohsen; Matthew D Heath; Gustavo Cabral-Miranda; Cyrill Lipp; Andris Zeltins; Marcos Sande; Jens V Stein; Carsten Riether; Elisa Roesti; Lisha Zha; Paul Engeroff; Aadil El-Turabi; Thomas M Kundig; Monique Vogel; Murray A Skinner; Daniel E Speiser; Alexander Knuth; Matthias F Kramer; Martin F Bachmann
Journal:  J Immunother Cancer       Date:  2019-04-26       Impact factor: 13.751

9.  Interaction of Cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo.

Authors:  Maria J Gonzalez; Emily M Plummer; Chris S Rae; Marianne Manchester
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

Review 10.  Reconceptualizing cancer immunotherapy based on plant production systems.

Authors:  Kathleen Hefferon
Journal:  Future Sci OA       Date:  2017-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.